Insulet’s (PODD) Buy Rating Reaffirmed at BTIG Research

Insulet (NASDAQ:PODD)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $370.00 price target on the medical instruments supplier’s stock. BTIG Research’s price target points to a potential upside of 10.36% from the company’s previous close.

A number of other brokerages also recently issued reports on PODD. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Piper Sandler lifted their target price on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Truist Financial boosted their target price on shares of Insulet from $365.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $374.10.

Insulet Trading Down 0.5%

PODD stock traded down $1.56 during trading on Thursday, reaching $335.28. 114,899 shares of the stock were exchanged, compared to its average volume of 715,931. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $23.59 billion, a price-to-earnings ratio of 102.08, a P/E/G ratio of 2.64 and a beta of 1.39. The business has a 50 day moving average price of $324.17 and a 200-day moving average price of $311.37. Insulet has a 1 year low of $230.05 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same quarter last year, the firm earned $1.08 EPS. The business’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that Insulet will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. True Wealth Design LLC grew its holdings in shares of Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the first quarter worth $26,000. Larson Financial Group LLC grew its position in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the period. Golden State Wealth Management LLC lifted its position in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares during the period. Finally, SouthState Corp boosted its stake in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.